Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03460990 |
| Consolidated Lead Sponsor | Vertex Pharmaceuticals |
| Therapeutic Condition Cohort | Respiratory and Pulmonary |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 116 participants (ACTUAL) |
| Registered Start Date | 2018-05-01 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| University of Alabama at Birmingham | Birmingham, AL | Open Hospital Dossier -> |
| Yale Cancer Center and Smilow Cancer Hospital | New Haven, CT | Open Hospital Dossier -> |
| Johns Hopkins Hospital and Kimmel Cancer Center | Baltimore, MD | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.